INSIGHTS ON LIQUID DOSE MANUFACTURING

• CDMO Uses Robotic Gloveless Isolator For Advanced Therapeutics

  CDMOs must innovate production architectures to meet the demands of advanced therapeutics to ensure a reliable supply and compliance. Discover how these approaches advance modern medicine and improve patient outcomes.

• Spray Dried Biologics For Nasal Dosage Forms

  A fireside chat explores spray drying for nasal biologics, covering formulation science, particle design, delivery advantages, and testing strategies to move from concept to clinic.

• Streamline Your Path To Clinical Fill

  Drug-independent PFS testing is a required early step — but it can be time-consuming and resource-intensive. What if you could eliminate the effort without losing the data you need?

• Solve ATMP Aseptic Filling Challenges With Gloveless Isolators

  Human intervention is the top contamination risk in ATMP manufacturing. Robotic gloveless isolators address that risk through full automation and real-time monitoring during aseptic filling.

• Service Solutions Designed To Help You Gain Speed To Clinic And Market

  4/28/2025

  Discover how speed, cost, and regulatory acceptance impact drug manufacturing, as well as learn about aseptic filling challenges and how innovative services can enhance your efficiency and compliance.

• Establishing A Container Closure System — Engineering For Integrity

  8/31/2026

  CCS design in aseptic manufacturing involves more than component selection. This article examines how elastomeric closures, barrier configurations, component formats, and plunger placement affect integrity and line performance.

• Protecting Your Drug Product: Integrating Engineering And Quality

  8/31/2026

  Engineering decisions in fill/finish directly shape product quality and sterility assurance. This article examines how inert gas purging, plunger placement, dosing verification, and barrier systems interact across line design.

• Why Lower Endotoxin Levels Matter: Raising The Bar For Patient Safety And Product Quality

  5/12/2026

  Strengthen patient safety and regulatory compliance with comprehensive endotoxin control strategies designed to support the evolving demands of injectable and advanced pharmaceutical products.

• Rethinking Fill-Finish To Reduce API Loss In Early Development

  6/15/2026

  Early-stage drug programs can preserve constrained API supplies by replacing large-scale manufacturing defaults with deliberate, right-sized fill-finish designs that minimize avoidable process waste.